AIM ImmunoTech Inc. (AIM)
D
Pipeline Grade
Financial Position (from SEC Filings)
$5.8M
Cash & Equivalents
$2.7M
Quarterly Burn Rate
6 mo
Est. Cash Runway
$8M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2027-04-30 | Phase2 Readout | — |
Active Clinical Trials (3)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT03734692 | Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer | PHASE2 | Active Not Recruiting | 24 |
| NCT03899987 | Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery | PHASE2 | Active Not Recruiting | 12 |
| NCT05927142 | Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic ... | PHASE2 | Recruiting | 43 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.